VCEL Vericel

Vericel to Present at the Morgan Stanley Global Healthcare and H.C. Wainwright Global Investment Conferences

Vericel to Present at the Morgan Stanley Global Healthcare and H.C. Wainwright Global Investment Conferences

CAMBRIDGE, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Company leadership will present at the upcoming Morgan Stanley and H.C. Wainwright investor conferences.

Nick Colangelo, President and CEO, and Joe Mara, CFO will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference at 8:00 a.m. ET on Tuesday, September 13, 2022. On Wednesday, September 14, 2022, Mr. Mara will engage in a fireside chat at 9:00 a.m. ET at the H.C. Wainwright 24th Annual Global Investment Conference.

Webcasts of both presentations will be available on the Investor Relations section of the Vericel Corporation website at: .

About Vericel Corporation

Vericel is a leader in advanced therapies for the sports medicine and severe burn care markets. The company markets two cell therapy products in the United States. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. The company also holds an exclusive license for North American commercial rights to NexoBrid®, a registration-stage biological orphan product for debridement of severe thermal burns. For more information, please visit .

Epicel® and MACI® are registered trademarks of Vericel Corporation. NexoBrid® is a registered trademark of MediWound Ltd. and is used under license to Vericel Corporation. © 2022 Vericel Corporation. All rights reserved.

Investor Contact: 

Eric Burns

 

+1 (734) 418-4411

Media Contact: 

Julie Downs

 



EN
06/09/2022

Underlying

VCELVericel

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Vericel

 PRESS RELEASE
Free
VCEL VERICEL

Vericel Reports First Quarter 2025 Financial Results and Raises Full-Y...

Vericel Reports First Quarter 2025 Financial Results and Raises Full-Year Profitability Guidance Record First Quarter MACI Revenue of $46.3 Million and First Quarter Total Revenue of $52.6 Million Approximately 400 MACI Arthro Surgeons Trained to Date, with Year-to-Date Biopsy Growth Over 30% for Trained Surgeons Second Quarter Total Revenue and MACI Revenue Growth Expected to be in the Low- to Mid-20% Range Full-Year 2025 Revenue Guidance Reaffirmed and Profitability Guidance Raised Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., May...

May 8, 2025 1 EN
 PRESS RELEASE
Free
VCEL VERICEL

Vericel to Present at the Bank of America Securities 2025 Healthcare C...

Vericel to Present at the Bank of America Securities 2025 Healthcare Conference on Wednesday, May 14, 2025 CAMBRIDGE, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will present at the Bank of America Securities 2025 Healthcare Conference at 12:20 p.m. ET (9:20 a.m. PT) on Wednesday, May 14, 2025. A webcast of the presentation will be available on the Investor Relations section of the Vericel Corporation website at: . About Vericel Corporation...

May 7, 2025 1 EN
 PRESS RELEASE
Free
VCEL VERICEL

Vericel to Report First-Quarter 2025 Financial Results on May 8, 2025

Vericel to Report First-Quarter 2025 Financial Results on May 8, 2025 CAMBRIDGE, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will report its first-quarter 2025 financial results on Thursday, May 8, 2025. Vericel’s management will host a conference call and webcast at 8:30 a.m. ET to discuss its financial results and business highlights. The live webcast can be accessed on the Investor Relations section of the Vericel website at . Please vi...

April 24, 2025 1 EN
 PRESS RELEASE
Free
VCEL VERICEL

Vericel to Present at Multiple Upcoming Investor Conferences

Vericel to Present at Multiple Upcoming Investor Conferences CAMBRIDGE, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will present at the following investor conferences: TD Cowen 45th Annual Health Care Conference on Wednesday, March 5, 2025Canaccord Genuity 2025 Musculoskeletal Conference on Monday, March 10, 2025Leerink Partners 2025 Global Healthcare Conference on Wednesday, March 12, 2025 A webcast of the presentations will be available...

March 4, 2025 1 EN
 PRESS RELEASE
Free
VCEL VERICEL

Vericel Reports Fourth Quarter and Full-Year 2024 Financial Results

Vericel Reports Fourth Quarter and Full-Year 2024 Financial Results Full-Year Total Revenue Growth of 20% to $237.2 Million, with MACI Revenue Growth of 20% and Burn Care Revenue Growth of 22% Full-Year Adjusted EBITDA Growth of 58% to $53.4 Million Record Fourth Quarter Gross Margin of 78%, Adjusted EBITDA Margin of 40%, and Net Income of $19.8 Million Mid-Term Profitability Targets Increased to Gross Margin in the High-70% Range and Adjusted EBITDA Margin in the High-30% Range Strong MACI Arthro Key Launch Indicators, with Approximately 250 MACI Arthro Surgeons Trained to Date 2025 F...

February 27, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch